Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta‐analysis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Respirology (Carlton South. Print)

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/resp.13276PMID 29502338
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

  2019cited by this paper
• Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice

  2017cited by this paper
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)

  2017cited by this paper
• Ten‐year trends in direct costs of asthma: a population‐based study

  2017cited by this paper
• Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma.

  2016cited by this paper
• Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

  2016cited by this paper
• Roflumilast Ameliorates Airway Hyperresponsiveness Caused by Diet-Induced Obesity in a Murine Model.

  2016cited by this paper
• Roflumilast for asthma: Efficacy findings in mechanism of action studies.

  2015cited by this paper
• Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.

  2015cited by this paper
• Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies.

  2015cited by this paper
• Roflumilast for asthma: Efficacy findings in placebo-controlled studies.

  2015cited by this paper
• The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma

  2014cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration

  2013cited by this paper
• Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.

  2013cited by this paper
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration

  2011cited by this paper
• Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects

  2011cited by this paper
• Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

  2009cited by this paper
• A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD

  2009cited by this paper
• Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma.

  2009cited by this paper
• Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast

  2007cited by this paper
• Efficacy and safety of roflumilast in the treatment of asthma.

  2006cited by this paper
• The Potential Role of Roflumilast: The New Phosphodiesterase-4 Inhibitor

  2006cited by this paper
• Roflumilast, a Phosphodiesterase 4 Inhibitor, Reduces Airway Hyperresponsiveness after Allergen Challenge

  2006cited by this paper
• Risk of severe asthma episodes predicted from fluctuation analysis of airway function

  2005cited by this paper
• Comparison of roflumilast, an oral anti‐inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma

  2005cited by this paper
• Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.

  2005cited by this paper
• Airway hyperresponsiveness

  2003cited by this paper
• Airway hyperresponsiveness.

  2003cited by this paper
• Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD).

  2003cited by this paper
• Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.

  2002cited by this paper
• The New Phosphodiesterase 4 Inhibitor Roflumilast Is Efficacious in Exercise‐Induced Asthma and Leads to Suppression of LPS‐Stimulated TNF‐α Ex Vivo

  2002cited by this paper
• Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

  2001cited by this paper
• In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

  2001cited by this paper
• Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.

  1999cited by this paper
• Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

  1998cited by this paper
• Tumour necrosis factor alpha: a polcnlial mediator of asthma

  1995cited by this paper

• Phosphodiesterase signaling in asthma: mechanistic insights and emerging therapeutic strategies.

  2026cites this paper
• Phosphodiesterase-4 Inhibitors in Chronic Obstructive Pulmonary Disease: Molecular Mechanisms, Current Therapeutics, and Future Perspectives.

  2026cites this paper
• A Systematic Review of Clinical Outcomes and Safety Profiles of PDE4 Inhibitors in Managing Psoriasis and Psoriatic Arthritis: Evidence Synthesis Spanning From 2012 to 2023

  2025cites this paper
• Severe asthma beyond bronchodilators: Emerging therapeutic approaches.

  2025cites this paper
• Neutrophilic asthma: current prospects. A review

  2024cites this paper
• Causal effects of pediatric asthma on psychiatric disorders: a bidirectional Mendelian randomization study

  2024cites this paper
• A comprehensive review of the intersection between asthma and depression

  2024cites this paper
• Inhaled braylin regulates Th2 response and induces relaxant effects in the airway muscles in a model of ovalbumin-induced asthma

  2023cites this paper
• Roflumilast ameliorates ovariectomy-induced depressive-like behavior in rats via activation of AMPK/mTOR/ULK1-dependent autophagy pathway.

  2023cites this paper
• Blood–Brain Barrier Rescue by Roflumilast After Transient Global Cerebral Ischemia in Rats

  2023cites this paper
• Clinical Implication of Phosphodiesterase-4-Inhibition

  2022cites this paper
• Current unmet needs and potential solutions to uncontrolled asthma

  2022cites this paper
• Stressed out - The role of oxidative stress in airway smooth muscle dysfunction in asthma and COPD.

  2022cites this paper
• Neutrophils and Asthma

  2022cites this paper
• Novel Therapeutic Strategies in Asthma-Chronic Obstructive Pulmonary Disease Overlap.

  2022cites this paper
• Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?

  2022cites this paper
• An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022

  2022cites this paper
• Pharmacologic Management Strategies of Asthma-Chronic Obstructive Pulmonary Disease Overlap.

  2022cites this paper
• Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Acute Lung Functional and Airway Remodeling Effects of an Inhaled Highly Selective Phosphodiesterase 4 Inhibitor in Ventilated Preterm Lambs Exposed to Chorioamnionitis

  2022cites this paper
• New Avenues for Phosphodiesterase Inhibitors in Asthma

  2021cites this paper
• Pathogenesis, clinical features of asthma COPD overlap (ACO), and therapeutic modalities.

  2021cites this paper
• Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.

  2020cites this paper
• Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long‐acting beta‐2‐agonist

  2020cites this paper
• Principal component analysis of routine blood test results with Parkinson's disease: A case-control study.

  2020cites this paper
• Cyclic AMP in dendritic cells: A novel potential target for disease‐modifying agents in asthma and other allergic disorders

  2020cites this paper
• The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice

  2020cites this paper
• Pathophysiological effects of intravenous phosphodiesterase type 4 inhibitor in addition to surfactant lavage in meconium‐injured newborn piglet lungs

  2020cites this paper
• Pharmacotherapeutic management of asthma in the elderly patient

  2020cites this paper
• [Obesity and asthma: Mechanisms and therapeutic options].

  2019cites this paper
• Asthma-COPD overlap: review of diagnosis and management.

  2019cites this paper
• Management of Asthma COPD Overlap.

  2019cites this paper
• Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.

  2019cites this paper
• Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.

  2019cites this paper
• Contemporary Concise Review 2018: Asthma and chronic obstructive pulmonary disease

  2019cites this paper
• An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma

  2019cites this paper
• Experimental and investigational phosphodiesterase inhibitors in development for asthma

  2019cites this paper
• Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease

  2018cites this paper